PT - JOURNAL ARTICLE AU - Nabi, Hani A. AU - Zubeldia, José M. TI - Clinical Applications of <sup>18</sup>F-FDG in Oncology DP - 2002 Mar 01 TA - Journal of Nuclear Medicine Technology PG - 3--9 VI - 30 IP - 1 4099 - http://tech.snmjournals.org/content/30/1/3.short 4100 - http://tech.snmjournals.org/content/30/1/3.full SO - J. Nucl. Med. Technol.2002 Mar 01; 30 AB - PET has emerged as a powerful diagnostic tool for the evaluation of cancer patients. Currently, most of these studies are performed with the glucose analog 18F-FDG, which has been shown to accumulate avidly in most tumors. 18F-FDG PET is now routinely used in the diagnosis, staging, and posttherapy evaluation of oncologic patients. After reading this paper, the reader should understand the physiologic basis of using 18F-FDG in patients with different tumors, describe the role of this radiopharmaceutical in the management of oncologic patients, and identify those malignancies for which 18F-FDG has proved to be effective in diagnosis and follow-up.